Branch of Imexpharm Corporation - Binh Duong Hi-Tech Plant

Imexpharm Pharmaceutical Joint Stock Company

Moxifloxacin (as Moxifloxacin hydroclorid)

400mg / 250mL

24 months

Solution for intravenous infusion

Box of 10 bags x 1 bottles x 250ml

VD-35545-22

05/01/2022

Antibiotics

Moxifloxacin 400 mg/250 ml solution for infusion is indicated for the treatment of:
- Community acquired pneumonia (CAP)
- Complicated skin and skin structure infections (cSSSI)
Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- Mild and moderate community-acquired pneumonia caused by Streptococcus pneumoniae, H. influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae or Moraxella catarrhalis.
- Uncomplicated skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes and treatment of complicated skin and skin structure infections caused by Staphylococcus aureus, Escherichia coli, K. pneumonia or Enterobacter cloacae. The drug is effective in the treatment of skin infections such as: Uncomplicated subcutaneous abscesses, furuncles, impetigo, cellulitis and other skin infections.
- Complicated intra-abdominal infections, including polymicrobial infections such as abscesses caused by susceptible organisms such as Bacteroides fragilis, B. thetaiotomicron, Clostridium perfringens, Enterococcus faecalis, E. coli, Proteus mirabilis, S. anginosus, S. constellatus or Peptostreptococcus.
- Uncomplicated urinary tract infections
- Acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, H. papainfluenzae, Klebsiella pneumoniae, Staphylococcus aureus, Moraxella catarrhalis.
- Treatment of acute sinus infections caused by susceptible organisms: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis.

The recommended dose is 400 mg moxifloxacin, infused once daily.
Renal/hepatic impairment
No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis.
There is insufficient data in patients with impaired liver function.
Elderly and in patients with low bodyweight.
No adjustment of dosage is required in the elderly and in patients with low bodyweight.
Children and people under 18 years old:
Moxifloxacin is contraindicated in children and growing adolescents.